Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 10Terminated 5Not yet recruiting 4Active not recruiting 3Withdrawn 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 17Head and Neck Neoplasms 14Pancreatic Neoplasms 11Lung Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma 7Glioblastoma 7Ovarian Neoplasms 6Lymphoma, Follicular 6Hematologic Neoplasms 6Uterine Cervical Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 5Leukemia 5Kidney Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Rectal Neoplasms 4

Interventions

Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Cancer Metastatic × 1 year × Clear all
NCT04031872 2025-09-05

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

The Netherlands Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡